Exelixis, Inc. (NASDAQ:EXEL) – Analysts at William Blair issued their Q1 2019 earnings per share (EPS) estimates for shares of Exelixis in a research note issued to investors on Monday. William Blair analyst A. Hsieh expects that the biotechnology company will post earnings per share of $0.27 for the quarter. William Blair also issued estimates for Exelixis’ Q2 2019 earnings at $0.30 EPS, Q3 2019 earnings at $0.33 EPS and Q4 2019 earnings at $0.35 EPS.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.18. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The firm had revenue of $152.50 million during the quarter, compared to the consensus estimate of $104.91 million. During the same quarter in the previous year, the business earned ($0.04) earnings per share. The firm’s quarterly revenue was up 145.2% compared to the same quarter last year.
A number of other equities research analysts also recently issued reports on the company. BidaskClub downgraded Exelixis from a “buy” rating to a “hold” rating in a research report on Friday. Oppenheimer reissued a “hold” rating on shares of Exelixis in a research report on Wednesday, January 17th. Cann reissued a “hold” rating on shares of Exelixis in a research report on Thursday, January 4th. Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price target for the company in a research report on Tuesday, January 2nd. Finally, SunTrust Banks reissued a “buy” rating and set a $38.00 price target on shares of Exelixis in a research report on Thursday, December 21st. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $32.13.
Exelixis (NASDAQ EXEL) traded up $0.96 during mid-day trading on Tuesday, reaching $30.40. The company’s stock had a trading volume of 2,631,897 shares, compared to its average volume of 2,860,000. Exelixis has a 1 year low of $16.72 and a 1 year high of $32.50. The stock has a market capitalization of $8,990.00, a P/E ratio of 62.04, a PEG ratio of 0.84 and a beta of 1.88.
In other news, Director Alan M. Garber sold 15,000 shares of the company’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total value of $454,500.00. Following the completion of the sale, the director now owns 64,829 shares of the company’s stock, valued at $1,964,318.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.10% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Mackenzie Financial Corp boosted its position in shares of Exelixis by 24.1% in the third quarter. Mackenzie Financial Corp now owns 10,116 shares of the biotechnology company’s stock worth $245,000 after buying an additional 1,963 shares during the period. Stifel Financial Corp boosted its position in shares of Exelixis by 2.8% in the third quarter. Stifel Financial Corp now owns 72,974 shares of the biotechnology company’s stock worth $1,768,000 after buying an additional 2,009 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Exelixis by 8.7% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 26,607 shares of the biotechnology company’s stock worth $645,000 after buying an additional 2,138 shares during the period. Swiss National Bank boosted its position in shares of Exelixis by 0.5% in the third quarter. Swiss National Bank now owns 489,200 shares of the biotechnology company’s stock worth $11,853,000 after buying an additional 2,300 shares during the period. Finally, Zacks Investment Management boosted its position in shares of Exelixis by 8.4% in the second quarter. Zacks Investment Management now owns 42,163 shares of the biotechnology company’s stock worth $1,038,000 after buying an additional 3,266 shares during the period. 80.92% of the stock is owned by institutional investors.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.